About this test
Detects activating EGFR mutations in exons 18 to 21, including exon 19 deletions, L858R and T790M, to guide EGFR inhibitor therapy.
- Clinical area
- Molecular oncology
- Method
- PCR / Sanger
- Sample
- FFPE tissue block
- Report languages
- EN · AR · RU
When to order
Advanced non-squamous NSCLC at diagnosis, and at progression on EGFR inhibitors.
Results are reported to the ordering physician and should be interpreted in clinical context.
Request this test
Offer this test to your patients.
Contract pricing and turnaround times are provided on request for laboratories and clinics.
Molecular oncology